Jeffrey Unger, MD
Family Medicine · Chino, CANPI 1003856188
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $646,573 of the $905,690 with a category attached, or 71.4%. 37 manufacturers reported payments, led by Abbott at 35.6% of the total. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,316 payments — averaging $688.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$323K
- Novo Nordisk$308K
- Corcept Therapeutics$130K
- Bayer$28K
- Amgen$25K
- Sanofi-aventis U.S. LLC$25K
- plus $67K from 31 others
Across 45 payments — averaging $18,013 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$752K
- Novo Nordisk AS$36K
- Sanofi US Services Inc.$21K
- Sanofi-aventis U.S. LLC$750
- Indivior Inc.$150
What the payments were for
- Consulting fees$129,01514%
- Speaking & faculty fees$646,57371%
- Travel & lodging$96,70811%
- Food & beverage$32,5954%
- Education$7400%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 571 | $322,764 |
| Novo Nordisk | 328 | $307,719 |
| Corcept Therapeutics | 165 | $130,335 |
| Bayer | 49 | $27,946 |
| Amgen | 37 | $24,953 |
| Sanofi-aventis U.S. LLC | 20 | $24,774 |
| Novo Nordisk AS | 9 | $12,564 |
| Lifescan, Inc. | 8 | $7,470 |
| Siemens Medical Solutions USA, Inc. | 5 | $6,581 |
| Recordati_rare_diseases_inc. | 6 | $6,155 |
| AbbVie(2 entities) | 33 | $6,018 |
| Teva Pharmaceuticals USA, Inc. | 9 | $5,397 |
| Cequr Corporation | 3 | $4,115 |
| Medtronic | 3 | $3,900 |
| Sanofi | 3 | $2,955 |
| Astellas Pharma US Inc | 1 | $2,388 |
| Xeris Pharmaceuticals, Inc. | 5 | $2,078 |
| Zealand Pharma US, Inc. | 2 | $2,000 |
| Dexcom, Inc. | 1 | $1,400 |
| AstraZeneca | 3 | $1,012 |
| Jazz Pharmaceuticals Inc. | 8 | $515 |
| Titan Pharmaceuticals, Inc. | 3 | $450 |
| Acadia Pharmaceuticals Inc | 7 | $312 |
| Axsome Therapeutics, Inc. | 3 | $263 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $200 |
| Radiometer America, Inc | 1 | $195 |
| Alkermes, Inc. | 6 | $195 |
| Mannkind Corporation | 5 | $179 |
| Insulet Corporation | 1 | $156 |
| Esperion Therapeutics, Inc. | 3 | $152 |
| Indivior Inc. | 8 | $131 |
| Antares Pharma, Inc. | 2 | $120 |
| Tandem Diabetes Care, Inc. | 2 | $109 |
| Lilly USA, LLC | 2 | $91 |
| Harmony Biosciences LLC | 1 | $45 |
| Lexicon Pharmaceuticals, Inc. | 1 | $34 |
| Radius Health, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$132,177
- Korlym$127,668
- FREESTYLE LIBRE 3$112,852
- FreeStyle Libre Pro$108,588
- Ozempic$84,531
- FreeStyle Libre$57,154
- FreeStyle Libre 2$35,210
- Victoza$33,184
- AIMOVIG$24,395
- TZIELD$22,102
- Kerendia$20,790
- Tresiba$20,276
- Atellica IM 1300 Analyzer$6,581
- Non-Covered$6,220
- Xultophy 100/3.6$6,211
- ISTURISA$6,155
- UBRELVY$5,464
- AJOVY$5,293
- CeQur Simplicity$4,091
- ZEGALOGUE$2,000
How this compares
$905,690 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 25 | $1,075,428 |
| NuplazidPimavanserin Tartrate | 23 | $124,999 |
| OzempicSemaglutide | 84 | $103,906 |
| KerendiaFinerenone | 84 | $81,512 |
| JardianceEmpagliflozin | 97 | $76,685 |
| FarxigaDapagliflozin Propanediol | 55 | $38,435 |
| Repatha SureclickEvolocumab | 35 | $25,484 |
| ProliaDenosumab | 12 | $19,611 |
| InvokanaCanagliflozin | 30 | $19,504 |
| WegovySemaglutide | 11 | $17,772 |
| LyumjevInsulin Lispro-Aabc | 17 | $15,913 |
| RybelsusSemaglutide | 17 | $15,081 |
| TradjentaLinagliptin | 12 | $12,859 |
| EliquisApixaban | 17 | $12,822 |
| Victoza 3-PakLiraglutide | 14 | $11,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $130,335 | $1,075,42825 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $307,719 | $136,759112 claims |
| Acadia Pharmaceuticals IncNuplazid | $312 | $124,99923 claims |
| BayerKerendia | $27,946 | $81,51284 claims |
| AstraZenecaFarxiga | $1,012 | $38,43555 claims |
| Lilly USA, LLCLyumjev, Humalog | $91 | $21,96138 claims |
| AmgenProlia | $24,953 | $19,61112 claims |
| AbbVieSynthroid | $6,018 | $4,56565 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Chino
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
- Monica BonakdarNewport Beach$307K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.